Nova Eye Medical Ltd · ASX:EYE
Nova Eye Medical — Shareholder Meeting (October 2026)
23 slides from Nova Eye Medical's shareholder meeting presentation, Oct 29, 2026
Slide 1: Nova Eye Medical 2026 Annual General Meeting
For personal use only Nova Eye Medical Limited (ASX: EYE) 2026 Annual General Meeting | 29 October 2026 | Tom Spurling, Managing Director
Slide 2: Disclaimer
Disclaimer For personal use only This presentation has been prepared by Nova Eye Medical Limited (ASX: EYE). While the information in this presentation has been prepared in good faith and with reasonable care, no representation or warranty, express or implied, is made as to the accuracy, adequacy or
Slide 3: Glaucoma is the second-leading cause of blindness in the developed world
Glaucoma is the second-leading cause of blindness in the developed world For personal use only Nova Eye Medical designs and builds devices that enable surgeons to treat patients with glaucoma. Our glaucoma solutions: ✓ Work with the body’s anatomy ✓ Open the natural outflow pathway ✓ Use surgical in
Slide 4: Four consecutive years of strong revenue growth
Four consecutive years of strong revenue growth 26% compound annual growth, FY22 to FY26 For personal use only US$23.7M US$18.8M US$15.2M US$11.3M US$9.5M FY22 FY23 FY24 FY25 FY26 Total sales. Sources: Nova Eye annual results FY22 to FY26. Nova Eye Medical (ASX: EYE) | 2026 Annual General Meeting |
Slide 5: Interventional glaucoma (IG) is the future
Interventional glaucoma (IG) is the future Surgeons treat the disease surgically and early, For personal use only instead of relying on drops and a wait-and-see approach Legacy approach 90%+ of patients don’t take their drops as Drops More drops Filtration surgery prescribed¹ ½ Interventional mindse
Slide 6: A US$944M interventional glaucoma market and just starting to grow
A US$944M interventional glaucoma market and just starting to grow For personal use only By 2035 5M vs 500K Category leader Glaukos projects US US cataract surgeries vs IG surgeries a year¹ ophthalmologists could perform as many IG procedures as cataract procedures² US$944M → US$1.6B 3-5% Global IG
Slide 7: Cataract surgeons are driving IG growth
Cataract surgeons are driving IG growth For personal use only The advent of IG means glaucoma treatment no longer relies only on glaucoma specialists. One in five cataract patients also has glaucoma, 10,000 (1) and interventions like iTrack Advance can be US cataract / comprehensive surgeons perform
Slide 8: iTrack Advance is built for interventional glaucoma
iTrack Advance is built for interventional glaucoma For personal use only Positioned perfectly within the IG movement. Other approaches bypass the pathway, cut tissue away, or leave an implant behind. iTrack Advance is different: it works with the eye’s anatomy. No tissue destruction. No implants. U
Slide 9: iTrack Advance is ready for the interventional movement
iTrack Advance is ready for the interventional movement For personal use only No trials to run. Approvals in place. No reimbursement to secure. Sales channels generating revenue. Trials Approval Reimbursement First revenue Revenue growth iTrack Advance ✓ ✓ ✓ ✓ ✓ Nova Eye Medical (ASX: EYE) | 2026 An
Slide 10: USA revenue growing faster than the market
USA revenue growing faster than the market USA market size (bars, US$M) and Nova Eye’s share of it (line) For personal use only 500 6.0% US$457M 450 US$426M US$394M US$397M 5.0% 400 5.1% US$365M EYE revenue/market size Market Size in US$ m 350 US$321M 4.4% 4.0% 300 3.6% 250 3.0% 200 2.9% 2.0% 150 2.
Slide 11: Operating results H2 FY26 and FY26
Operating results H2 FY26 and FY26 Hit FY26 guidance: 25%+ revenue growth and EBITDA positive in H2 FY26 For personal use only US$'000 H2 FY25 H2 FY26 FY25 FY26 Revenue 10,393 12,724 18,777 23,651 Gross margin % 70% 73% 68% 72% Total operating expenditure (7,527) (8,758) (15,598) (17,252) EBITDA fro
Slide 12: Operating Expenditure Leverage
Operating Expenditure Leverage Sales growth and cost control improving the bottom line For personal use only Expenditure as a percentage of revenue H1 FY24 H2 FY24 H1 FY25 H2 FY25 H1 FY26 H2 FY26 Sales 100% 100% 100% 100% 100% 100% Gross margin 70% 74% 66% 70% 70% 73% Operating expenditure Sales and
Slide 13: Q1 FY27 Quarterly Update
Nova Eye Medical 2026 Annual General Meeting ASX: EYE For personal use only Q1 FY27 Quarterly Update Quarter ended 30 September 2026
Slide 14: Q1 FY27 key takeaways
Q1 FY27 key takeaways Growth accelerating. Cash flow and EBITDA positive. For personal use only US$6.3M US$25.1M Q1 sales, up 30% on PCP Last twelve months sales, up 30% A$0.5M US$26-31M Operating cash inflow in the quarter; FY27 sales guidance (ex-China) confirmed positive EBITDA Nova Eye Medical (
Slide 15: Q1 FY27 sales up 30% on PCP
Q1 FY27 sales up 30% on PCP USA +25%, Germany +24%, rest of world +44%. October USA sales ~30% on PCP For personal use only US$'000 Q1 FY26 Q1 FY27 Growth USA 4,142 5,189 25% Germany 403 499 24% Direct markets 4,545 5,688 25% Rest of world 309 444 44% Sales (excl China) 4,854 6,132 26% China - 158 -
Slide 16: Last twelve months sales of US$25.1M, up 30%
Last twelve months sales of US$25.1M, up 30% LTM growth accelerated from 26% at June 2026 For personal use only US$'000 LTM Sep 2025 LTM Sep 2026 Growth USA 15,338 19,739 29% Germany 1,910 2,128 11% Direct markets 17,248 21,866 27% Rest of world 1,248 2,146 72% Sales (excl China) 18,496 24,012 30% C
Slide 17: USA: Q1 FY27 sales up 25% on PCP
USA: Q1 FY27 sales up 25% on PCP Seasonally softer than a record Q4, well ahead of last year For personal use only $6M $5.5M $5M $5.2M Up 25% $4.5M $4.5M Q1 FY27 vs Q1 FY26 $4.1M $4.1M $4M $3.5M US$1.8M $3M annualised revenue per sales rep (Q1 FY26: US$1.6M) $2.0M $2M $1.7M $1.9M $1.8M Additional sa
Slide 18: Cash flow from operations turned positive
Cash flow from operations turned positive A$0.5M inflow in Q1 FY27 For personal use only 1,000 500 515 A$4.1M - liquidity at 30 September 2026 -500 (200) A$2.1M cash -1,000 (847) (798) A$2.0M (1,011) (1,161) (1,174) (1,285) -1,500 (1,377) (1,515) undrawn debt facility (1,792) -2,000 -2,500 (2,322) (
Slide 19: Plan to report in US$ from December 2026
Plan to report in US$ from December 2026 For personal use only Company expects to change its reporting currency to US$ for the six months ending 31 December 2026 : • More than 90% of the revenues of the Company are invoiced in US$ • Approximately 85% of the operating costs of the Company are incurre
Slide 20: FY27 guidance confirmed
FY27 guidance confirmed Strong start: Q1 sales ex-China up 26% on PCP For personal use only US$26-31M 15%-37% FY27 sales, excluding China growth on FY26 sales (ex-China) Good October 2026 sales +26% EBITDA + Q1 FY27 sales ex-China vs PCP Positive EBITDA planned for FY27; A$4.1M liquidity covers it N
Slide 21: Nova Eye is growing 30% a year, in a market that's just getting started
Nova Eye is growing 30% a year, in a market that’s just getting started For personal use only We built our business for this exact opportunity. 30% 3-5% Early Revenue growth (last twelve of the USA addressable Growth market in early months), positive EBITDA in market captured: room to commercial rol
Slide 22: Contact information
Contact information For personal use only Tom Spurling Mark Flynn Managing Director Investor Relations +61 8 8836 0193 +61 416 068 733 [email protected] [email protected] Nova Eye Medical (ASX: EYE) | 2026 Annual General Meeting | 22
Slide 23: Thank You
Nova Eye Medical 2026 Annual General Meeting ASX: EYE For personal use only Thank You
Nova Eye Medical — Shareholder Meeting (October 2026) on 6ix